Trials / Completed
CompletedNCT01666106
Osteonecrosis of the Jaw (ONJ) Case Registry
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 327 (actual)
- Sponsor
- Amgen · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Osteonecrosis of the Jaw (ONJ) Case Registry
Detailed description
The purpose of the ONJ case registry is to describe the natural history of positively-adjudicated ONJ in subjects with cancer with an observation period of 5 years. Most of these subjects are expected to have received bone antiresorptive agents such as bisphosphonates or denosumab together with cancer-specific therapies (eg, chemotherapy, steroids, or anti-angiogenics). It is also possible that the registry will include subjects with cancer who developed ONJ without exposure to any antiresorptive therapy.
Conditions
Timeline
- Start date
- 2012-10-01
- Primary completion
- 2020-12-16
- Completion
- 2020-12-16
- First posted
- 2012-08-16
- Last updated
- 2020-12-21
Locations
64 sites across 11 countries: United States, Belgium, Canada, Denmark, Finland, France, Germany, Greece, Italy, Spain, United Kingdom
Source: ClinicalTrials.gov record NCT01666106. Inclusion in this directory is not an endorsement.